Parathyroid hormone
Natpar, Natpara (parathyroid hormone) is a protein pharmaceutical. Parathyroid hormone was first approved as Natpara on 2015-01-23. It is used to treat hypocalcemia and hypoparathyroidism in the USA. It has been approved in Europe to treat hypoparathyroidism. It is known to target prolactin-releasing peptide receptor, parathyroid hormone 2 receptor, and parathyroid hormone/parathyroid hormone-related peptide receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Natpara
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypocalcemia | HP_0002901 | D006996 | E83.51 |
| hypoparathyroidism | — | D007011 | E20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
parathyroid hormone, Natpara, Takeda Pharmaceuticals U.S.A., Inc. | |||
| 2122-01-23 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
457 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Secondary hyperparathyroidism | D006962 | EFO_1001173 | — | 5 | 7 | 20 | 11 | 15 | 57 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | 10 | 15 | 11 | 5 | 12 | 50 |
| Hypoparathyroidism | D007011 | HP_0000829 | E20 | 5 | 8 | 12 | 4 | 19 | 46 |
| Primary hyperparathyroidism | D049950 | EFO_0008519 | E21.0 | 3 | 4 | 6 | 1 | 26 | 37 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | 6 | 3 | 3 | 2 | 18 | 32 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | 1 | 2 | 4 | 9 | 13 | 28 |
| Chronic renal insufficiency | D051436 | — | N18 | 2 | 3 | 12 | 4 | 6 | 26 |
| Parathyroid diseases | D010279 | — | E21.5 | — | 1 | 5 | 1 | 19 | 26 |
| Parathyroid neoplasms | D010282 | — | — | 1 | 2 | 4 | 2 | 16 | 25 |
| Hypercalcemia | D006934 | HP_0003072 | E83.52 | 1 | 3 | 3 | 2 | 9 | 17 |
Show 28 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | 4 | 4 | 1 | — | 1 | 9 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | 1 | 3 | — | 2 | 6 |
| Digeorge syndrome | D004062 | — | D82.1 | 2 | 2 | 1 | — | — | 4 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 2 | — | 1 | 3 |
| Dialysis | D003956 | — | — | — | — | 1 | — | 2 | 3 |
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | 1 | 2 | — | 1 | 3 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | 1 | — | 2 | 3 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | 1 | — | 1 | 2 |
| Spontaneous abortion | D000022 | EFO_1001255 | O00.1 | — | 1 | 1 | — | — | 1 |
| Hyperphosphatemia | D054559 | HP_0002905 | — | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 6 | 1 | — | — | 1 | 8 |
| Head and neck neoplasms | D006258 | — | — | 1 | 2 | — | — | 2 | 5 |
| Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | — | 3 |
| Kidney transplantation | D016030 | — | — | — | 1 | — | — | 2 | 3 |
| Bone diseases | D001847 | — | M89.9 | — | 1 | — | — | 2 | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 1 | — | — | — | 2 |
| Vascular calcification | D061205 | — | — | — | 1 | — | — | 1 | 2 |
| Osteoporotic fractures | D058866 | — | — | — | 1 | — | — | 1 | 2 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | 2 | — | — | — | 2 |
| Bone resorption | D001862 | — | — | 1 | 1 | — | — | 1 | 2 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thyroidectomy | D013965 | — | — | 1 | — | — | — | 9 | 10 |
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | 1 | 8 |
| Endocrine bone diseases | D001849 | — | — | 2 | — | — | — | 1 | 3 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | 1 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | — | — | — | — | 2 |
| Goiter | D006042 | HP_0000853 | E04.9 | 1 | — | — | — | 1 | 2 |
| Familial hypophosphatemic rickets | D053098 | — | — | 1 | — | — | — | — | 1 |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | 1 | — | — | — | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
| Stem cell transplantation | D033581 | — | — | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Papillary thyroid cancer | D000077273 | — | — | — | — | — | — | 3 | 3 |
| Hyperthyroidism | D006980 | — | E05.9 | — | — | — | — | 3 | 3 |
| Parathyroidectomy | D016105 | — | — | — | — | — | — | 3 | 3 |
| Pseudohypoparathyroidism | D011547 | — | E20.1 | — | — | — | — | 3 | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 2 | 2 |
| Multiple organ failure | D009102 | EFO_1001373 | — | — | — | — | — | 2 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 2 | 2 |
| Menopause | D008593 | EFO_0003922 | N95 | — | — | — | — | 2 | 2 |
| Endocrine gland neoplasms | D004701 | EFO_0003769 | D35 | — | — | — | — | 2 | 2 |
| Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | — | 1 | 1 |
Show 62 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Parathyroid hormone |
| INN | parathyroid hormone |
| Description | Parathyroid hormone (PTH), also called parathormone or parathyrin, is a peptide hormone secreted by the parathyroid glands that regulates the serum calcium concentration through its effects on bone, kidney, and intestine.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >3FFD:A|Monoclonal antibody, heavy chain, Fab fragment
EVQLVESGGDLVKPGGSLKLSCAASGFTFSSYGMSWIRQTPDKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLY
LQMSSLKSEDTAMFYCARQTTMTYFAYWGQGTLVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWN
SGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSPRPSETVTCNVAHPASSTKVDKKIEPA
>3FFD:B|Monoclonal antibody, light chain, Fab fragment
QLVLTQSSSASFSLGASAKLTCTLSSQHSTYTIEWYQQQPLKPPKYVMDLKQDGSHSTGDGIPDRFSGSSSGADRYLSIS
NIQPEDEAMYICGVGDTIKEQFVYVFGGGTKVTVLGEPKSTPTLTVFPPSSEELKENKATLVCLISNFSPSGVTVAWKAN
GTPITQGVDTSNPTKEGNKFMASSFLHLTSDQWRSHNSFTCQVTHEGDTVEKSLSPAECL |
Identifiers
| PDB | 1BL1, 1BWX, 1BZG, 1ET1, 1FVY, 1HPH, 1HPY, 1HTH, 1M5N, 1ZWA, 1ZWB, 1ZWC, 1ZWD, 1ZWE, 1ZWF, 1ZWG, 2L1X, 3C4M, 3FFD, 3H3G, 3L2J, 4YD8, 4Z8J, 5EMB, 6FJ3, 6NBF, 6NBH, 6NBI, 6XT9, 7F16, 7UZO, 7UZP, 7VVJ, 7VVK, 7VVL, 7VVM, 7VVN, 7VVO, 7Y35, 7Y36, 8BIA, 8BJ0, 8D51, 8D52, 8FLQ, 8FLR, 8FLS, 8FLT, 8FLU, 8GW8, 8HA0, 8HAF, 8HAO, 8JR9, 8T5F |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108078 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | N19A0T0E5J (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PRLHR
PRLHR
PTH2R
PTH2R
PTH1R
PTH1R
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 79,212 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,011 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use